TransMedics Group (TMDX) Q3 Revenue Beat; Raises FY Revenue Guidance

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of ($0.78), $0.62 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $49.19 million.

GUIDANCE:

TransMedics Group sees FY2023 revenue of $222-230 million, versus prior of $180-$190 million and the consensus of $194.18 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral